Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
Umbilical
Cord Blood
Next-generation therapeutic innovation derived from the youngest cells
Umbilical cord blood–derived stem cells are among the healthiest and most primitive cells, obtained from the umbilical cord and placenta that connect the mother and fetus, and possess high potential for immunomodulatory and regenerative therapies. Kangstem Biotech Co., Ltd uses only umbilical cord blood collected from natural deliveries at 36 weeks of gestation or later, ensuring uniform quality as well as ethical and non-invasive cell procurement. Based on this approach, the company is developing next-generation regenerative medicine therapies for patients with rare and intractable diseases.
